New York (AP) - A third leading candidate COVID-19 vaccine has entered a final stage of human testing in the United States.
AstraZeneca announced Monday its potential COVID-19 vaccine has entered final trials in the U.S. to test the effectiveness and safety of the product.
The Cambridge, England-based company said the trial will involve up to 30,000 adults from various racial, ethnic, and geographic groups.
The potential vaccine was invented by the University of Oxford and an associated company, Vaccitech.
Meanwhile, a U.S. advisory panel is suggesting a way to ration the first limited doses once a vaccine does prove safe and effective.